Trial · NCT00993655

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

NCT00993655, Phase 2, Completed, Canadian Cancer Trials Group; results first posted 2017-08-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer. Trials, record NCT00993655. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00993655

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
NCT number: NCT00993655
Status: Completed
Phases: Phase 2
Enrollment: 275 participants, actual
Lead sponsor: Canadian Cancer Trials Group
Conditions: Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: carboplatin, cisplatin, paclitaxel
First posted: 2009-10-12
Last updated: 2023-08-28
Results first posted: 2017-08-10

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	9-month Progression Rate Post-randomization	9 months	It is defined as proportion of patients who had progressed at or before 9 months after randomization, i.e., the time from the randomization to the date when the first observation of disease progression (earliest of the date when the first CA 125 meets progression definition and the date of first objective relapse or progression, defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, recorded) has been documented or when death due to any cause has been observed was less than or equal to 9 months.
Secondary	Progression Free Survival	During the study with median follow-up of 33 months	Time from the day of randomization until the time when first observation of disease progression (earliest of the dates of first CA125 which meets progression definition and first objective relapse or progression defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, has been documented or when death due to any cause has been observed.
Secondary	Overall Survival	During the study with median follow-up of 33 months	Time from the day of randomization to death from any cause.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	9-month Progression Rate Post-randomization	9 months	All randomized patients	Porportion of participants	NUMBER
SECONDARY	Progression Free Survival	During the study with median follow-up of 33 months	All patients randomized to the study	months	MEDIAN
SECONDARY	Overall Survival	During the study with median follow-up of 33 months		months	MEDIAN

Source ClinicalTrials.gov

Results by group9

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
9-month Progression Rate Post-randomization	Arm 1	0.386		Porportion of participants
9-month Progression Rate Post-randomization	Arm 2	0.347		Porportion of participants
9-month Progression Rate Post-randomization	Arm 3	0.245		Porportion of participants
Progression Free Survival	IV Carboplatin + IV Paclitaxel	11.3	95% Confidence Interval 8.8 to 14.7	months
Progression Free Survival	IP Cisplatin + IV/IP Paclitaxel	12.7	95% Confidence Interval 9.7 to 18.0	months
Progression Free Survival	IP Carboplatin + IV/IP Paclitaxel	12.5	95% Confidence Interval 10.8 to 15.0	months
Overall Survival	IV Carboplatin + IV Paclitaxel	38.1	95% Confidence Interval 32.9 to 47.7	months
Overall Survival	IP Cisplatin + IV/IP Paclitaxel	40.6	95% Confidence Interval 38.7 to 68.1	months
Overall Survival	IP Carboplatin + IV/IP Paclitaxel	59.3	95% Confidence Interval 34.2 to 68.3	months

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm 1	101
Overall Study	STARTED	Arm 2	72
Overall Study	STARTED	Arm 3	102
Overall Study	COMPLETED	Arm 1	101
Overall Study	COMPLETED	Arm 2	72
Overall Study	COMPLETED	Arm 3	102
Overall Study	NOT COMPLETED	Arm 1	0
Overall Study	NOT COMPLETED	Arm 2	0
Overall Study	NOT COMPLETED	Arm 3	0

Source ClinicalTrials.gov

Adverse events234

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Febrile neutropenia	Blood and lymphatic system disorders	Arm 1	5	95
other	Febrile neutropenia	Blood and lymphatic system disorders	Arm 2	1	67
other	Febrile neutropenia	Blood and lymphatic system disorders	Arm 3	1	92
other	Palpitations	Cardiac disorders	Arm 1	6	95
other	Palpitations	Cardiac disorders	Arm 2	0	67
other	Palpitations	Cardiac disorders	Arm 3	1	92
other	Hearing impaired	Ear and labyrinth disorders	Arm 1	7	95
other	Hearing impaired	Ear and labyrinth disorders	Arm 2	3	67
other	Hearing impaired	Ear and labyrinth disorders	Arm 3	4	92
other	Tinnitus	Ear and labyrinth disorders	Arm 1	5	95

1 to 10 of 234Source ClinicalTrials.gov

See all 234 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Arm 1	34	95
Total, all-cause mortality	Arm 2	24	67
Total, all-cause mortality	Arm 3	26	92
Total, other adverse events	Arm 1	94	95
Total, other adverse events	Arm 2	64	67
Total, other adverse events	Arm 3	92	92
Total, serious adverse events	Arm 1	7	95
Total, serious adverse events	Arm 2	8	67
Total, serious adverse events	Arm 3	6	92

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
29186319	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00993655

GET https://conductscience.org/api/trials/v1/NCT00993655/events?page=2

API reference For AI assistants